Cellular Rejuvenation Therapy
Neural Exosomes
The brain communicates in vesicles. Exosomes are how that signal moves. They are not cells. They do not divide. They carry the signal a cell would have sent.
These therapies are not FDA-approved to treat, cure, or prevent any disease.
What an exosome actually is
An exosome is a tiny membrane-bound packet that a cell releases to talk to other cells. Thirty to one hundred fifty nanometers across, an exosome carries a specific cargo: proteins, lipids, microRNAs, mRNAs, growth factors, and surface markers that tell the receiving cell what to do next. Inflammation, repair, immune regulation, and tissue maintenance are all coordinated this way.
In our regenerative program, the exosomes we work with come from mesenchymal stem cells. The MSCs themselves are not transferred to the patient. The exosomes are isolated, characterized, and quantified before being made available for clinical use. A 1 mL vial contains roughly 110 billion exosomes by particle count.
The reason this matters for brain work is straightforward: the brain’s natural repair signaling depends heavily on small vesicles crossing tight cellular junctions. Neural exosomes, by their size and surface chemistry, participate in that signaling in ways that a larger cell or a free growth factor cannot.
Where they fit in a neurological case
Neural exosomes are not a first-line intervention and they are not a one-size protocol. They enter the conversation after the Diagnostic Process has surfaced neuroinflammatory or post-injury signatures that the published literature has implicated as exosome-responsive. The decision to use them, and at what dose, is made by your physician on the basis of your specific findings.
The cases where we most often have the conversation about exosomes are post-COVID neurological presentations, late-stage post-concussion syndromes, post-stroke recovery plateaus, and early-stage neurodegenerative processes where conventional care has run out of moves and the patient wants a clinically grounded next option.
Administration route, dose, and frequency are determined by the treating physician based on the clinical picture. There is no standardized protocol because there is no standardized patient.
Where they come from
The neural exosomes we use are sourced from a domestic FDA-registered HCT/P establishment. Donor mothers are screened for medical history, lifestyle, and three generations of family genetic history. Tissue is collected after full-term, healthy Cesarean births, processed in a CLIA-certified laboratory under 21 CFR Part 1271, and quarantined for 14 days while bacterial, viral, fungal, mycoplasmal, and protozoal contamination tests run.
No expansion. No cell culture. No additives that would push the product out of HCT/P status. The chain of custody is 100% documented from donor through processing to clinic.
The state of the art has advanced quickly in the last several years. The gap between fully-credentialed, domestically-processed biologic vendors and the rest of the market is now wide enough that the choice of supplier is itself a clinical decision. We associate only with vendors who can document every step from donor screening through processing to the vial in front of the patient. Provenance is non-negotiable.
Frequently asked
What is an exosome?
An exosome is a small membrane-bound vesicle (30–150 nanometers) that cells release as part of normal communication. Exosomes carry proteins, lipids, microRNAs, and other signaling molecules. They participate in cell-to-cell messaging, immune regulation, and tissue maintenance throughout the body.
How do neural exosomes differ from generic exosomes?
Neural exosomes are sourced from mesenchymal stem cells and formulated for central nervous system signaling. The cargo composition (microRNA profile, growth factor content, surface markers) is selected for its relevance to neural tissue. They are not interchangeable with the exosome products marketed for cosmetic or orthopedic use.
How are they administered?
Administration is determined by the treating physician based on clinical context and the patient’s individual case. Route, dose, and frequency are decided after the Diagnostic Process and are not standardized across patients.
What is the evidence base?
Preclinical work on exosome signaling in neurological models is well-developed in the peer-reviewed literature (PubMed indexes thousands of papers on neural exosomes and brain injury, neurodegeneration, and stroke). Clinical evidence in humans is earlier-stage and largely consists of case series, observational data, and ongoing investigational work. We discuss what the evidence does and does not support during every consultation.
Is this FDA-approved?
Exosome products of this class do not go through FDA-approval like pharmaceutical products do. Instead, they are highly regulated by the FDA under 21 CFR Part 1271 as HCT/Ps, intended for homologous use under the direction of a licensed provider. The FDA does not review or approve these products for the diagnosis, treatment, cure, or prevention of any disease; instead, they oversee the manufacturing process to ensure that the cellular products are safe and free of contaminants so that they are safe to be administered to patients in support of their natural healing processes.
Start with the consultation.
Whether neural exosomes belong in your protocol is a clinical decision, not a marketing one. The first conversation is complimentary.
Request a Discovery Consultation